Damora Therapeutics (DMRA) Net Cash Flow (2019 - 2026)
Damora Therapeutics (DMRA) posted Net Cash Flow of $275.3 million for Q1 2026, up 45787.17% on a QoQ basis from $600000.0 in Q4 2025, and up 11388.36% year-over-year from N/an in Q1 2025.
Damora Therapeutics (DMRA) Net Cash Flow (2019 - 2026) Analysis & Trends
Damora Therapeutics' Net Cash Flow history runs 8 years deep, the most recent figure standing at $275.3 million for Q1 2026.
- Quarterly Net Cash Flow rose 11388.36% year-over-year to $275.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $271.1 million (up 3065.99% YoY) and the FY2025 annual result came in at $242.8 million, up 3593.09% from the prior year.
- Net Cash Flow was $275.3 million for Q1 2026 at Damora Therapeutics, up from $600000.0 in the prior quarter.
- Across five years, Net Cash Flow topped out at $275.3 million in Q1 2026 and bottomed at -$17.0 million in Q1 2022.
- A 5-year average of $12.9 million and a median of -$2.1 million in 2023 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow plunged 19573.68% — and 2026, when it soared 11388.36%.
- Damora Therapeutics' Net Cash Flow stood at $2.9 million in 2022, then plunged by 163.9% to -$1.9 million in 2023, then tumbled by 160.22% to -$4.9 million in 2024, then soared by 112.24% to $600000.0 in 2025, then surged by 45787.17% to $275.3 million in 2026.
- Business Quant data shows DMRA's Net Cash Flow at $275.3 million in Q1 2026, $600000.0 in Q4 2025, and -$2.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Damora Therapeutics | 1.00 Bn | 798.11 Mn | - | 275.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 275.32 Mn |
| Mar 31, 2026 | 275.32 Mn |
| Dec 31, 2025 | 600,000.00 |
| Dec 31, 2025 | 600,000.00 |
| Sep 30, 2025 | -2.62 Mn |
| Sep 30, 2025 | -2.62 Mn |
| Jun 30, 2025 | -2.24 Mn |
| Jun 30, 2025 | -2.24 Mn |
| Mar 31, 2025 | -2.44 Mn |
| Mar 31, 2025 | -2.44 Mn |
| Dec 31, 2024 | -4.90 Mn |
| Dec 31, 2024 | -4.90 Mn |
| Sep 30, 2024 | -3.70 Mn |
| Sep 30, 2024 | -3.70 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Jun 30, 2024 | 1.90 Mn |
| Mar 31, 2024 | -250,000.00 |
| Mar 31, 2024 | -250,000.00 |
| Dec 31, 2023 | -1.88 Mn |
| Dec 31, 2023 | -1.88 Mn |